Turkey TITCK Pharmaceutical Import: A 2026 Guide for UK Exporters

Turkey is one of the largest pharmaceutical markets bridging Europe and the Middle East. It has a substantial domestic manufacturing base, a regulator whose decisions are watched across the region, and a hospital network that still relies on imported originator and specialty medicines for the cases its local supply cannot cover. For a hospital pharmacist in Istanbul or Ankara, a Ministry of Health procurement officer, an NGO supporting refugee health programmes, or a licensed Turkish distributor, the practical question is usually the same: how do you bring in a UK-licensed medicine in a way the regulator will accept, on a timeline that works for the patient.

That process runs through one authority: the Turkish Medicines and Medical Devices Agency, known by its Turkish initials TITCK. This guide explains how TITCK works, the routes a UK-licensed medicine can take into Turkey, the documentation involved, and how supply from an MHRA-licensed UK wholesale exporter fits the pathway in 2026. It is written for the buyer side, the people in Turkey sourcing UK-licensed product, rather than for regulatory consultants.

One point to set out plainly at the start. Euro Biom is a UK MHRA-licensed wholesale exporter supplying UK-licensed, MHRA-authorised finished medicines. We do not manufacture, and we are not a regulatory consultancy. Where this guide describes registration mechanics, those are the buyer's and local representative's responsibilities in Turkey. Our role is the UK supply leg and the documentation that supports it.

What TITCK Is and What It Controls

The Turkish Medicines and Medical Devices Agency operates under the Ministry of Health as the national regulator for human medicines and medical devices. Within the pharmaceutical remit it is responsible for marketing authorisation (commonly called registration), Good Manufacturing Practice inspection and certification, import control, laboratory analysis of products, pharmacovigilance, and the technical side of pricing and reimbursement.

Several features of TITCK matter for a UK exporter and a Turkish buyer:

• It follows a structure aligned with EU practice. TITCK reviews dossiers in the Common Technical Document (CTD) format and references international guidelines. This helps UK-licensed product, because a medicine carrying MHRA documentation, evidence of approval, GMP evidence and full batch records maps closely onto the format TITCK expects.
• GMP sits at the centre of the process. TITCK places strong weight on Good Manufacturing Practice for the manufacturing site, and a GMP assessment, whether by on-site inspection or by acceptance of equivalent evidence, is a key gate in the pathway. A UK manufacturing site already operating under MHRA GMP oversight starts from a recognised position.
• It controls pricing. Pharmaceutical pricing in Turkey is regulated through a reference-pricing system, and price approval is part of bringing a registered product to market, set within the regulated framework rather than freely by the supplier.

For the country-level overview of how Euro Biom supplies this market, see our UK pharmaceutical exporter to Turkey page, and for how Turkey sits alongside neighbouring regulators see the regulator comparison tool.

Routes into the Turkish Market

A UK-licensed medicine generally reaches a Turkish hospital or patient by one of two broad routes. Choosing correctly at the outset saves months.

1. Full TITCK registration

This is the route for any product supplied routinely and at volume. The foreign manufacturer or marketing authorisation holder, represented by a locally established Turkish authorised representative, submits a CTD dossier to TITCK. The agency reviews the quality, safety and efficacy documentation, assesses GMP for the manufacturing site, may require samples for laboratory analysis, sets a regulated price, and grants a marketing authorisation. Registration is what allows a product to be tendered, stocked and dispensed across the market on an ongoing basis.

2. Named-patient and Foreign Drug Supplier import (for an unregistered or unavailable medicine)

Where a medicine is not registered in Turkey, or is registered but not currently available, it can still be brought in through Turkey's named-patient framework. This is the route most relevant to specialty, oncology and rare-disease cases where no registered local equivalent exists. Importantly, this is the buyer's in-country mechanism for importing a product that already holds a marketing authorisation somewhere else, for example a UK-licensed medicine. It is not a route for supplying an unlicensed product: the medicine itself is a properly authorised UK product, and the named-patient permission is simply the Turkish regulatory route to bring it in for a defined clinical need.

Under this framework, products not commercialised in Turkey are handled through designated Foreign Drug Suppliers, which include the Turkish Pharmacists Association economic enterprise (commonly referred to as TEB) and the Social Security Institution. The request is supported by a prescription issued by a practitioner licensed in Turkey, and the supplied product is recorded in the national drug monitoring system so it can be tracked through the supply chain. Our named patient supply service describes how the UK side of this is handled.

Documentation TITCK Expects

For a full registration, the TITCK dossier follows the CTD structure and is supported by a set of country-of-origin certificates and GMP evidence. The table below sets out the core documents a UK-licensed product will typically need, and who issues each one.

Two practical points sit behind that table.

Apostille and legalisation. Documents issued abroad generally have to be apostilled or consulate-legalised before TITCK will accept them. Turkey is a party to the Apostille Convention, so for UK-issued certificates the apostille route is normally available, which is more efficient than full consular legalisation. Documents must also be translated into Turkish by an authorised translator and notarised. Build this step in early, because legalisation and translation queues are a common and avoidable source of delay.

The CPP and GMP evidence are the documents buyers underestimate. TITCK wants assurance that the product is genuinely approved in its country of origin and made to GMP. The CPP issued by the MHRA under the WHO certification scheme, together with current GMP evidence for the manufacturing site, is the cleanest way to provide that, and MHRA CPPs take time to obtain, so request them well ahead of a submission window. For the broader UK-side picture, see our guide to UK pharmaceutical import documentation.

How UK-Licensed Supply Fits the TITCK Pathway

There is a structural reason UK-licensed product travels well into Turkey. TITCK is looking for assurance that a medicine is properly authorised, manufactured to GMP, and traceable batch by batch. A UK-licensed, MHRA-authorised finished medicine arrives with exactly that evidence already in place: a marketing authorisation, a manufacturer operating under MHRA GMP oversight, a CPP available from the MHRA, and Qualified Person batch release with a Certificate of Analysis per batch. Because TITCK uses the CTD format and recognises stringent-authority documentation, the UK paperwork does not have to be reconstructed for the Turkish system, it has to be assembled, apostilled, translated and presented.

It is worth being precise about what UK-licensed supply means here. It means finished medicines that hold a UK marketing authorisation and are released to the UK market, not unlicensed specials. Across every route, full registration or named-patient import, the product Euro Biom supplies is a UK-licensed, MHRA-authorised medicine. The named-patient or Foreign Drug Supplier permission is a feature of the Turkish buyer's import route, not a change in the licensed status of the product.

Cold Chain and GDP for the Turkey Lane

A meaningful share of the specialty medicines that move from the UK to Turkey are temperature sensitive. Where that is the case, Good Distribution Practice and validated cold chain are part of what keeps the consignment compliant and the product usable on arrival. The controls that matter on this lane are:

• Validated temperature-controlled storage in the UK at the labelled storage condition before despatch.
• Qualified shipping containers appropriate to the route and to the ambient profile expected on the journey to Istanbul or Ankara, including the warmer ground temperatures of the summer months.
• Continuous temperature monitoring with a calibrated data logger accompanying the consignment, so the temperature history can be reviewed on arrival.
• A GDP-compliant transport chain from the UK warehouse, through air freight, to the Turkish importer or hospital, with a documented procedure for handling any temperature excursion.

Heathrow proximity makes the UK an efficient origin for this lane, with direct air links to Turkish airports and short despatch times for urgent cases. For more, see our UK cold chain pharmaceutical supply page and the pharma cold chain logistics guide.

Common Pitfalls and How to Avoid Them

The same handful of issues account for most delays on Turkey-bound supply. Each is straightforward to design out at the start.

1. Treating apostille and translation as an afterthought

Certificates that are not properly apostilled, legalised, or translated and notarised will not be accepted. This is procedural rather than scientific, but it stops a submission cold. Map the apostille and translation chain for every certificate before you start.

2. Underestimating the GMP gate

GMP assessment of the manufacturing site is central to TITCK approval and can affect the timeline significantly. Confirm the current GMP status and documentation for the exact manufacturing site early, and align it with the dossier rather than treating it as a late addition.

3. An out-of-date or wrong-format CPP

The CPP must genuinely confirm the UK-licensed status of the specific product and site, and it has a shelf life of its own. Request it early and check that it names the correct manufacturing site and approved particulars.

4. Confusing the two routes

Pushing an individual patient case through the full registration machinery, or assuming a named-patient import substitutes for registration in routine supply, both waste time. Match the route to the clinical and commercial reality up front.

5. Cold chain without a deviation procedure

A validated shipment can still see an excursion. Without an agreed deviation-handling procedure between supplier and consignee, an excursion can leave a consignment in limbo. Agree the procedure before the first shipment.

6. Leaving the local representative decision to last

The Turkish marketing authorisation holder or authorised representative is central to the whole process, from dossier submission to pricing and import. Their standing and systems materially affect speed, so this is not a box to tick cheaply at the end.

How Euro Biom Supports Buyers in Turkey

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We supply UK-licensed, MHRA-authorised finished medicines and operate the UK leg of a TITCK-compliant import, working with hospital pharmacies, Ministry of Health buyers, NGOs and licensed Turkish distributors and their local representatives. Across the TITCK pathway, our role typically covers:

• UK-side documentation. Coordinating the MHRA Certificate of Pharmaceutical Product and GMP evidence with the manufacturer or marketing authorisation holder, and assembling the GDP export pack: batch release certificate, Certificate of Analysis, packing list and commercial invoice.
• Named-patient and Foreign Drug Supplier supply. Supplying the UK-licensed product, with the country-of-origin documentation the Turkish importer needs to support an application for an individual patient or cohort.
• Cold-chain logistics. GDP-validated temperature-controlled storage, qualified shipping containers, calibrated data loggers, and despatch from near Heathrow to Turkey.
• Shortage and urgent supply. Rapid response on UK-licensed lines where Heathrow proximity and same-week despatch are decisive.

For more, see our UK pharmaceutical exporter to Turkey page, our guide to UK pharmaceutical import documentation, and an overview of our services.